Royalty Pharma (RPRX) Net Cash Flow Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-14,223.53% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Royalty Pharma |
23.13 Bn |
25.57 Bn |
- |
-120.35% |
| Date | Value |
|---|
| Mar 31, 2026 |
-120.35% |
| Dec 31, 2025 |
-1,423.10% |
| Sep 30, 2025 |
137.69% |
| Jun 30, 2025 |
-149.46% |
| Mar 31, 2025 |
-56.64% |
| Dec 31, 2024 |
95.42% |
| Sep 30, 2024 |
34.13% |
| Jun 30, 2024 |
366.92% |
| Mar 31, 2024 |
38.14% |
| Dec 31, 2023 |
-163.89% |
| Sep 30, 2023 |
-10.77% |
| Jun 30, 2023 |
-37.64% |
| Mar 31, 2023 |
5.78% |
| Dec 31, 2022 |
376.84% |
| Sep 30, 2022 |
-269.53% |
| Jun 30, 2022 |
-26.98% |
| Mar 31, 2022 |
183.53% |
| Dec 31, 2021 |
52.26% |
| Sep 30, 2021 |
185.66% |
| Jun 30, 2021 |
-76.23% |
